PT93245B - Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem Download PDF

Info

Publication number
PT93245B
PT93245B PT93245A PT9324590A PT93245B PT 93245 B PT93245 B PT 93245B PT 93245 A PT93245 A PT 93245A PT 9324590 A PT9324590 A PT 9324590A PT 93245 B PT93245 B PT 93245B
Authority
PT
Portugal
Prior art keywords
group
general formula
asp
gly
val
Prior art date
Application number
PT93245A
Other languages
English (en)
Portuguese (pt)
Other versions
PT93245A (pt
Inventor
Leo Alig
Albrecht Edenhofer
Marcel Muller
Arnold Trzeciak
Thomas Weller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT93245A publication Critical patent/PT93245A/pt
Publication of PT93245B publication Critical patent/PT93245B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
PT93245A 1989-02-23 1990-02-22 Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem PT93245B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH66989 1989-02-23
CH426589 1989-11-29

Publications (2)

Publication Number Publication Date
PT93245A PT93245A (pt) 1990-08-31
PT93245B true PT93245B (pt) 1996-01-31

Family

ID=25685313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93245A PT93245B (pt) 1989-02-23 1990-02-22 Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem

Country Status (18)

Country Link
US (1) US5663297A (cs)
EP (1) EP0384362B1 (cs)
JP (1) JPH0662672B2 (cs)
AT (1) ATE187737T1 (cs)
AU (1) AU633872B2 (cs)
CA (1) CA2008116C (cs)
CZ (1) CZ282730B6 (cs)
DE (1) DE59010889D1 (cs)
DZ (1) DZ1396A1 (cs)
ES (1) ES2141079T3 (cs)
FI (1) FI900864A0 (cs)
HU (1) HUT52784A (cs)
IL (1) IL93422A (cs)
MC (1) MC2097A1 (cs)
NO (1) NO900839L (cs)
NZ (1) NZ232591A (cs)
PT (1) PT93245B (cs)
RU (1) RU2024549C1 (cs)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
NZ235564A (en) * 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
GB9007751D0 (en) * 1990-04-05 1990-06-06 Ciba Geigy Ag Novel platelet-aggregation inhibitors
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
US5264420A (en) * 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5481021A (en) * 1991-03-06 1996-01-02 G. D. Searle & Co. Phenyl amidines derivatives useful as platelet aggregation inhibitors
US5321034A (en) * 1991-05-07 1994-06-14 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1992019595A1 (en) * 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
DK0513675T3 (da) * 1991-05-13 1996-09-30 Fujisawa Pharmaceutical Co Hidtil ukendt peptidforbindelse samt fremgangsmåde til fremstilling deraf
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5565449A (en) * 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en) * 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5389631A (en) * 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5206373A (en) * 1992-02-28 1993-04-27 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
CA2144763A1 (en) * 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
US5786373A (en) * 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5358956A (en) * 1992-10-14 1994-10-25 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
AU692439B2 (en) * 1993-03-29 1998-06-11 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
WO1994022834A1 (en) * 1993-03-29 1994-10-13 Zeneca Limited Heterocyclic derivatives as platelet aggregation inhibitors
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
KR100445309B1 (ko) * 1993-07-01 2004-11-12 메르크 파텐트 게엠베하 콜라겐-자극혈소판응집에대한억제제
US5397791A (en) * 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists
MX9605270A (es) * 1994-05-04 1997-10-31 Bayer Ag Amidas de acidos tiocarboxilicos aromaticas substituidas.
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
US6387880B1 (en) 1994-10-24 2002-05-14 G.D. Searle & Co. Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
US5811398A (en) * 1995-04-11 1998-09-22 G. D. Searle & Co. Platelet aggregation inhibitors containing C-terminal aminergic side chain amino acid residues
US5789421A (en) * 1995-10-26 1998-08-04 Merck & Co., Inc. Fibrinogen receptor antagonist
US5952306A (en) * 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
AU713676B2 (en) * 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
WO1999019294A1 (en) * 1997-05-14 1999-04-22 Aventis Pharmaceuticals Products Inc. Legal/Patents Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
CA2291708A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
EP1030831A4 (en) * 1997-10-10 2003-01-02 Aventis Pharm Prod Inc PREPARATION OF AZACYCLOALKYLALCANOYL PSEUDOTETRAPEPTIDES
AU736951C (en) 1998-03-19 2003-02-20 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
EP2590634B1 (en) 2010-07-09 2016-03-09 BHV Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
EP0275748B1 (fr) * 1986-12-15 1992-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists

Also Published As

Publication number Publication date
US5663297A (en) 1997-09-02
EP0384362A3 (de) 1992-03-18
AU633872B2 (en) 1993-02-11
IL93422A0 (en) 1990-11-29
FI900864A0 (fi) 1990-02-21
IL93422A (en) 1994-11-28
NO900839D0 (no) 1990-02-22
NZ232591A (en) 1992-11-25
CS9000745A2 (en) 1991-08-13
DZ1396A1 (fr) 2004-09-13
EP0384362A2 (de) 1990-08-29
EP0384362B1 (de) 1999-12-15
HUT52784A (en) 1990-08-28
NO900839L (no) 1990-08-24
CZ282730B6 (cs) 1997-09-17
HU900735D0 (en) 1990-04-28
AU4994090A (en) 1990-09-20
PT93245A (pt) 1990-08-31
ES2141079T3 (es) 2000-03-16
JPH02264795A (ja) 1990-10-29
RU2024549C1 (ru) 1994-12-15
CA2008116C (en) 2001-11-20
CA2008116A1 (en) 1990-08-23
DE59010889D1 (de) 2000-01-20
ATE187737T1 (de) 2000-01-15
JPH0662672B2 (ja) 1994-08-17
MC2097A1 (fr) 1991-02-15

Similar Documents

Publication Publication Date Title
PT93245B (pt) Processo para a preparacao de novos derivados de glicina e de composicoes farmaceuticas que os contem
FI77875C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider.
EP0352249A1 (en) Novel platelet-aggregation inhibitors
EP0253190B1 (en) Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them
EP0214659A2 (en) Peptide derivatives, process for the production thereof and pharmaceutical compositions containing same
US5183804A (en) Polypeptide comprising repeated cell-adhesive core sequences
US4438029A (en) Synthetic peptides
US5236903A (en) Polypeptide comprising repeated cell-adhesive core sequences
HU199879B (en) Process for producing hexapeptides and pharmaceutical compositions comprising same as active ingredient
AU684511B2 (en) Oligopeptides derived from C-reactive protein fragments
RU2134695C1 (ru) Антитромботические азациклоалкилалканоилпептиды
JPS63303998A (ja) 新規なａｎｆ誘導体
IE45738B1 (en) Peptide derivatives and pharmaceutical compositions containing same
HU185229B (en) Process for preparing pharmaceutically active peptides and acetates thereof
IE42249B1 (en) Octapeptide derivatives having an oxygen or sulfur containing moiety in the c-terminal position
US4247543A (en) Organic compounds
US6342481B1 (en) Oligopeptides derived from C-reactive protein fragments
US6274705B1 (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
JP2617700B2 (ja) 細胞接着活性コア配列の繰り返し構造からなるポリペプチド
EP0190597A2 (en) Retro-inverso analogs of the bradykinin potentiating peptide bpp 5a
JPH024767A (ja) 薬理作用を有するペプチド類
JPS63141996A (ja) 新規活性ペプチド
GB1568195A (en) Synthetc peptides
JPS63141998A (ja) 新規活性ペプチド
JPS59110661A (ja) 置換ペプチド及びその製造方法、並びに該ペプチドを含有する医薬

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19951004

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000430